Valuation: Verastem, Inc.

Market Cap 1.17B 1.05B 970M 878M 1.64B 112B 1.67B 11.57B 4.62B 58.49B 4.4B 4.31B 185B P/E 2026 *
-5.93x
P/E 2027 * -7.19x
Enterprise Value 985M 883M 814M 737M 1.38B 93.84B 1.4B 9.71B 3.88B 49.11B 3.7B 3.62B 156B EV / Sales 2026 *
8.85x
EV / Sales 2027 * 7.37x
Free-Float
99.19%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Verastem, Inc.

1 day-0.05%
1 week-5.28%
Current month+18.14%
1 month+18.14%
3 months+55.90%
6 months+74.18%
Current year+23.19%
1 week 9.34
Extreme 9.3416
10.25
1 month 6.7
Extreme 6.7
10.25
Current year 3.43
Extreme 3.43
10.25
1 year 3.43
Extreme 3.43
10.82
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
39.6
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 2023-07-31
Director of Finance/CFO 39 2022-10-30
Chief Tech/Sci/R&D Officer - 2024-04-17
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 2023-07-31
Director/Board Member 69 2017-05-02
Date Insider Type Main position Quantity % Market Cap. Importance
10/1/26 Sell

Chief Financial Officer

-2,566 0.0042%
10/1/26 Sell

Chief Executive Officer

-44,121 0.0717%
9/21/26 Sell

Chief Financial Officer

-55 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
-0.36%-5.28%+3.03%+52.89% 1.17B
-0.62%+0.50%+33.92%+60.07% 64.38B
+1.42%+4.22%+16.06%+86.37% 56.16B
+0.94%+2.15%+15.58%+107.19% 54.16B
-1.96%-3.77%+24.18%+51.74% 45.33B
+0.60%-1.85%+20.25%+98.62% 42.25B
-0.58%+0.32%+218.65%+922.29% 40.78B
+3.08%+45.76%+109.51%+93.57% 33.8B
-0.26%-2.57%+12.55%+45.18% 32.25B
-1.29%-2.88%+21.60%-11.92% 23.57B
Average +0.13%+3.51%+47.53%+150.60% 39.39B
Weighted average by Cap. +0.17%+3.33%+49.30%+160.08%

Financials

2026 *2027 *
Net sales 111M 99.69M 91.97M 83.23M 156M 10.6B 158M 1.1B 438M 5.55B 418M 409M 17.57B 159M 143M 132M 119M 223M 15.16B 226M 1.57B 626M 7.93B 597M 585M 25.12B
Net income -170M -153M -141M -127M -238M -16.23B -242M -1.68B -670M -8.49B -640M -626M -26.9B -179M -160M -148M -134M -250M -17.01B -254M -1.76B -702M -8.9B -670M -656M -28.19B
Net Debt -188M -169M -156M -141M -263M -17.93B -268M -1.86B -741M -9.38B -707M -692M -29.72B -
Projected Income Statement - Annual - Verastem, Inc.
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
26-10-30 $9.645 -0.16% 571,332
26-10-29 $9.660 -1.78% 1,939,759
26-10-28 $9.835 -2.62% 2,809,016
26-10-27 $10.10 +1.00% 4,708,399
26-10-26 $10.00 -0.40% 4,289,252
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Verastem, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
9.660USD
Average target price
17.11USD
Spread / Average Target
+77.13%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Verastem, Inc.
  1. Stock Market
  2. Stocks
  3. VSTM Stock